Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

FinancialNewsMedia.com News Commentary

PALM BEACH, Fla, Nov. 15, 2022 /PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one factor driving expansion in the COPD drug market. The growth of the chronic obstructive pulmonary disease (COPD) drug market is being fueled by the rising demand for medications to treat COPD symptoms such as shortness of breath, coughing, mucus production, and wheezing, as well as the convenience and ease of using these treatments and therapies in the comfort of one's own home. A better understanding of respiratory illnesses, their treatments, and the necessary precautions has an additional effect on the market for medications used to treat chronic obstructive pulmonary disease (COPD). The value of the market for treatments for chronic obstructive pulmonary disease is boosted by the increased funding of R&D and drug production by governments and pharmaceutical corporations. Asthma and COPD are on the rise, and the senior population is also on the rise, thus these are three main factors pushing the industry forward.  A report from Market Research Future projected that the Chronic Obstructive Pulmonary Disease Market is expected to grow at CAGR of 4.5 % to reach USD 25.7 Billion by during the forecast period 2020-2027.  Active companies in the markets this week include Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), BioRestorative Therapies Inc. (NASDAQ:BRTX), MiMedx Group, Inc. (NASDAQ:MDXG), NanoViricides Inc. (NYSE:NNVC), Vericel Corporation (NASDAQ:VCEL).